PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Clinical trials for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL) trials appear
Sign up with your email to follow new studies for PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo aims to boost CAR-T power against rare lymphoma
Disease control Recruiting nowThis study tests whether adding the drug pembrolizumab to standard CAR-T cell therapy can improve outcomes for people with a rare type of lymphoma (PMBCL) that has come back or not responded to prior treatment. About 35 adults will receive the combination and be monitored for 6 m…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE2 • Sponsor: Jennifer Crombie, MD • Aim: Disease control
Last updated May 26, 2026 11:36 UTC
-
Double-Barreled CAR t cells take on tough lymphomas
Disease control Recruiting nowThis early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for people with non-Hodgkin lymphoma that has come back or not responded to standard treatments. The main goals are to check safety and find the right…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated May 26, 2026 11:34 UTC
-
New CAR T-Cell therapy targets tough lymphoma cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: Verismo Therapeutics • Aim: Disease control
Last updated May 26, 2026 11:32 UTC
-
Gene therapy breakthrough targets Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: Vironexis Biotherapeutics Inc. • Aim: Disease control
Last updated May 26, 2026 11:31 UTC
-
New study follows CAR-T cells in blood cancer patients
Disease control Recruiting nowThis study looks at how well CAR-T cell therapy works for people with certain blood cancers like lymphoma and leukemia. Researchers will track the CAR-T cells in the body after infusion and measure how the disease responds. The study includes 45 patients who have not improved aft…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Disease control
Last updated May 26, 2026 11:08 UTC
-
New CAR T-Cell therapy offers hope for Tough-to-Treat lymphoma
Disease control Recruiting nowThis trial tests a new CAR T-cell therapy called WZTL-002 in 60 people with large B-cell lymphoma that has returned or not responded to standard chemotherapy. Participants receive their own modified immune cells to attack the cancer, and doctors will check how many achieve comple…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE2 • Sponsor: Malaghan Institute of Medical Research • Aim: Disease control
Last updated May 26, 2026 08:20 UTC
-
New CAR-T therapy targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new treatment called CLIC-2201 for people with certain blood cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. The treatment uses a patient's own immune cells, which are modified in a lab to better rec…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated May 22, 2026 13:50 UTC
-
Engineered immune cells take on Hard-to-Treat lymphoma in new trial
Disease control Recruiting nowThis study tests a new treatment called TC011, which uses a patient's own immune cells modified to find and attack cancer cells. It is for adults with large B-cell lymphoma that has come back or not responded to at least two prior treatments. The trial aims to find the safest dos…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: TICAROS Co., Ltd. • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Double-target CAR-T therapy takes on blood cancers that won't quit
Disease control Recruiting nowThis study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to treat adults with B-cell blood cancers like lymphoma and leukemia that have not responded to other treatments. The therapy uses the patient's own immune cells, w…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: PHASE1, PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
Lifestyle plan aims to boost Well-Being in lymphoma survivors
Symptom relief Recruiting nowThis study tests whether a personalized healthy lifestyle plan can improve quality of life for people who have survived certain types of lymphoma (Hodgkin lymphoma, DLBCL, or PMBCL). Participants must be between 18 and 50 years old and in remission for 3 to 10 years. The study wi…
Matched conditions: PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMBCL)
Phase: NA • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Symptom relief
Last updated May 22, 2026 14:02 UTC